Yamazaki T, Yazaki Y
Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo, Japan.
J Hum Hypertens. 1999 Jan;13 Suppl 1:S43-7; discussion S49-50. doi: 10.1038/sj.jhh.1000747.
In an in vivo study, spontaneously hypertensive rats (SHR) were treated with an angiotensin II (Ang II) type 1 receptor antagonist of candesartan or hydralazine. Untreated SHR progressively developed severe hypertension, and treatment with candesartan or hydralazine decreased blood pressure. Candesartan reduced left ventricular (LV) weight, LV wall thickness, transverse myocyte diameter, the relative amount of V3 myosin heavy chain, and interstitial fibrosis, while treatment with hydralazine slightly prevented an increase in LV wall thickness, but did not exert a significant reduction on other parameters. In an in vitro study, neonatal rat cardiomyocytes were cultured on deformable silicone dishes. Stretching cardiomyocytes activated second messengers such as protein kinase C, Raf-1 kinase, and mitogen-activated protein (MAP) kinase, increasing protein synthesis, enhancing endothelin (ET)-1 release, activating the Na+/H+ ion exchanger. Moreover, pretreatment with candesartan diminished an increase in phenylalanine incorporation, MAP kinase activity, and c-fos gene expression induced by the stretching of cardiomyocytes. This suggests that the cardiac renin-angiotensin system is linked to the formation of pressure-overload hypertrophy and that Ang II increases the growth of cardiomyocytes by an autocrine mechanism. Finally, we examined the signalling pathways leading to MAP kinase activation both in cardiac myocytes and in cardiac fibroblasts. Ang II-evoked signal transduction pathways differed between cell types. In cardiac fibroblasts, Ang II activated MAP kinase through a pathway including the Gbetagamma subunit of Gi protein, Src, Shc, Grb2, and Ras, while Gq and protein kinase C were important in cardiac myocytes.
在一项体内研究中,自发性高血压大鼠(SHR)接受了坎地沙坦或肼屈嗪这两种血管紧张素II(Ang II)1型受体拮抗剂的治疗。未经治疗的SHR逐渐发展为严重高血压,而坎地沙坦或肼屈嗪治疗可降低血压。坎地沙坦降低了左心室(LV)重量、LV壁厚度、横向肌细胞直径、V3肌球蛋白重链的相对含量以及间质纤维化,而肼屈嗪治疗仅轻微阻止了LV壁厚度的增加,但对其他参数没有显著降低作用。在一项体外研究中,新生大鼠心肌细胞在可变形的硅胶培养皿上培养。拉伸心肌细胞可激活蛋白激酶C、Raf-1激酶和丝裂原活化蛋白(MAP)激酶等第二信使,增加蛋白质合成,增强内皮素(ET)-1释放,激活Na+/H+离子交换器。此外,用坎地沙坦预处理可减少由心肌细胞拉伸诱导的苯丙氨酸掺入增加、MAP激酶活性和c-fos基因表达。这表明心脏肾素-血管紧张素系统与压力超负荷肥大的形成有关,并且Ang II通过自分泌机制增加心肌细胞的生长。最后,我们研究了导致心肌细胞和成纤维细胞中MAP激酶激活的信号通路。Ang II诱发的信号转导通路在不同细胞类型之间存在差异。在心脏成纤维细胞中,Ang II通过包括Gi蛋白的Gbetagamma亚基、Src、Shc、Grb2和Ras的途径激活MAP激酶,而Gq和蛋白激酶C在心肌细胞中起重要作用。